I need a publish-ready narrative review that examines how the latest genomic technologies are reshaping cancer research, with a sharp eye on where the knowledge still falls short. Rather than cataloguing every study, the manuscript should weave together key findings—next-generation sequencing, single-cell analyses, CRISPR screens, long-read platforms—and critique the blind spots these tools reveal (or sometimes create) across tumour biology, diagnosis and therapy development. The central thread must be highlighting the unanswered questions and methodological limitations that deserve future funding and lab time. Scope • Roughly 5,000–7,000 words, written for a high-impact oncology journal. • Current primary literature only (2018-2024 preferred) sourced from PubMed, Web of Science and Google Scholar. • Clear section structure: introduction, technology overviews, thematic gap analysis, concise future-direction paragraph, conclusion. • Vancouver-style references, fully cross-checked. Deliverables 1. Main manuscript in Word and Google Docs. 2. Annotated bibliography (.RIS or .BIB). 3. One summary table of critical gaps per technology. 4. Up to two simple figures or graphical abstracts (PowerPoint or PNG). Acceptance criteria • Insightful synthesis—not a catalogue—demonstrating critical appraisal of at least 80 peer-reviewed articles. • All statements backed by citations; no uncited claims. • Grammarly and Turnitin checks below 10 % similarity. • Ready for peer-review with journal guidelines followed. Timeline and any preferred journal formatting can be discussed once we connect.